Playback speed
10 seconds
Primary Results of the Phase III SHINE Study: Ibrutinib in Combination With Bendamustine, Rituximab & Rituximab Maintenance as 1L Therapy for Older Patients With Mantle Cell Lymphoma
By
ecancer
FEATURING
Michael Wang
By
ecancer
FEATURING
Michael Wang
517 views
June 23, 2022
This video was recorded prior to FDA approval of Pirtobrutinib on January 26, 2023 in ...
read more ↘ Mantle Cell Lymphoma.
↖ read less
read more ↘ Mantle Cell Lymphoma.
↖ read less
Login to view comments.
Click here to Login